Welcome to the 3rd Next-Generation Conjugates Summit

Collaboration and combining expertise across different modalities remain a high priority for next-generation conjugate developers, and the 3rd Next-Generation Conjugates Summit returns as a hotbed of discussions.


To offer a new level of depth, the 2024 meeting will now be split into a Discovery and Development track to explore novel design concepts and how to progress a novel conjugate into and through the clinic. We also look forward to a new exploration of how novel conjugates can be utilized beyond cancer in our Non-Oncology Focus Day!

Join Your Peers To:

Explore advancements in novel targeting moiety and payload technology to gain successful therapeutic effects in various non-oncology indications, from Duchenne Muscular Dystrophy, to Obesity and Diabetes at our Non-Oncology Focus Day with Dyne TherapeuticsRegeneron, and J&J

Survey the diverse scope of innovation in novel technology beyond traditional mAbs and payloads in our Discovery Stream with Almac Discovery, Elucida Oncology, Antikor and Dantari
Uncover the most exciting clinical advancements from case-study-led sessions to get one step ahead of your clinical development and improve chances of progression into the clinic and beyond with VincerX Pharma, Zymeworks, Clarity Pharmaceuticals and Dyne Therapeutics


Share your thoughts and collaborate in our deep-dive workshop sessions to optimize the pairing of your novel format and target to guide your R&D and set up for success in your next-generation conjugate development with Eli Lilly & Co, Debiopharm, and Abzena



Develop improved manufacturing and CMC strategies to prepare for your inevitable manufacturing processes to streamline your downstream development with Mersana and Radiopharm Theranostics

Companies Previously Attended:

Join 150+ likeminded conjugate developers working in Chemistry, Conjugation, Discovery, Preclinical Development, Translation, Manufacturing and more!

Companies Attending Novel Format Conjugates Summit

What Your Peers Have to Say

‘With the explosion of antibody conjugates with different payloads, this is a terrific opportunity for colleagues to come together and share challenges and learnings across different modalities’ - Amgen

‘This year’s format with separate discovery and development tracks is particularly exciting. While equally important, it should provide a unique opportunity to focus, connect and share insights on new formats, payloads, linkers, targets and combinations thereof – and collaborate with fellow innovators in the space!’ - Dantari

Several 1st generation conjugates have been approved and presently are being used in clinic. They demonstrated significant advantages compared to older therapies and significantly extended survival for many patients. However, they all suffer from dose-limiting toxicities and rarely result in durable remission. The promise of next-generation conjugates is more targeted approach with better efficacy and safety, which is a very exciting prospect.’  - Alpha Cancer Technologies

'I’m excited to share our developing stories with worldwide experts, learn from them about novel technologies, and look for potential collaborations.' - Coherent Biopharma

‘The Next-Generation conjugates is a rapidly evolving field, with many exciting developments ongoing that could have a big impact on many patients lives. Therefore, I am thrilled to team up with the world experts in the Conjugation field and hear update the latest developments’ - Araris Biotech